To enhance drug conveyance and healing outcomes, pharmacokinetic study and in vivo suitability of anti-malarial drugs co-encapsulated inside Tween 80 niosomes were investigated. The survey utilized an exhaustive approach to address the strength of the niosomal details, drug discharge profiles, and exemplification proficiency. The issue of further developed opposition much of the time plagues drugs utilized for malaria treatment and prevention. This renders them unfit for monotherapy and reduces their usefulness. Assuming they are repackaged and mixed properly, many of these neglected anti-malarial medications may eventually make it back into the therapeutic system. The effectiveness of niosome-encased curcumin (CC) and primaquine (PRI) as an anti-malarial combination is compared to that of the two drugs alone. Treatment with a mix of 35 mg/kg of CC plus either 5 mg/kg or 1 mg/kg of PRI resulted in complete anti-malarial action and 20 days of survival in Plasmodium berghei-infected mice. Expanded assurance and endurance rate were associated with counteraction in recrudescence with the hazardous based PRI-CC combo treatment. The review's findings suggest that a baneful-based PRI-CC combo treatment could be a promising malaria treatment approach.